Bright Eye Hospital Group Co., Ltd. Class A

Bright Eye Hospital Group Co., Ltd. Class A

SSZSE:301239
33.02
CNY
-1.37
(-3.98%)
0.56EPS
64.67P/E
4.78BMarket Cap
May 04Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.81
10.06
10.94
12.13
15.3
13.42
18.16
17.88
18.83
20.39
Basic EPS, GAAP
-0.13
0.31
0.45
0.97
0.84
0.16
1.79
-0.68
-0.41
0.49
Free Cash Flow per Basic Share
-0.78
0.05
-1.29
0.72
0.94
-0.07
-0.08
-1.07
2.14
- -
Dividend per Share
- -
- -
0.01
0.01
0.04
0.07
0.18
0.52
0.12
0.36
Book Value per Share
3.53
4.85
6.63
7.6
8.45
13.82
15.32
14.05
13.65
14.36
Tangible Book Value per Share
3.17
4.48
6.15
7.14
8.08
13.57
12.36
11.01
10.61
10.3
Basic Weighted Avg Shares
103
101
109
112
112
129
150
150
149
149
Sales/Revenue/Turnover
806
1,016
1,193
1,362
1,710
1,726
2,718
2,678
2,797
3,043
Operating Margin (%)
3.08
6.82
8.33
100
11.3
6.11
13.95
3.85
5.1
9.13
Depreciation Expense
30
32
42
106
182
215
274
316
333
- -
Net Income, GAAP
-13
31
49
109
94
21
268
-102
-61
74
Effective Tax Rate (%)
716.94
41.68
39.22
28.77
32.4
65.27
23.25
- -
529.21
46.17
Profit Margin (%)
-1.66
3.08
4.11
8
5.49
1.19
9.86
-3.8
-2.18
2.43
Working Capital
20
81
186
140
-70
605
172
-30
-8
-17
LT Debt
- -
- -
18
852
885
1,025
1,451
1,575
1,619
1,526
Total Equity
353
485
744
853
948
2,068
2,318
2,121
2,067
2,180
Return on Invested Capital (%)
- -
8.95
9.01
8.83
4.99
0.86
7.8
- -
-3.29
2.27
Return on Capital (%)
- -
8.24
8.4
8.89
6.61
1.51
8.38
- -
-3.75
1.74
Return on Common Equity (%)
- -
7.47
7.98
13.64
10.42
1.36
12.29
-4.64
-2.94
3.46

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
349
446
451
LT Borrowings
471
364
326
LT Finance Leases
1,223
1,221
1,200
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
150
150
150
Market Capitalization
5,282
4,556
4,785

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,044
1,007
1,020
Cash, Cash Equivalents & STI
572
534
553
Accounts Receivable, Net
93
93
85
Inventories
226
227
228
Total Current Liabilities
899
1,014
1,037
Payables & Accruals
- -
- -
- -
ST Debt
349
446
451
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.05%
-2.56%
Free Cash Flow
- -
171.65%
-298.5%
Net Income, GAAP
- -
186.49%
-40.19%
Sales/Revenue/Turnover
- -
17.39%
4.44%
Total Cash Common Dividend
- -
136.06%
-77.23%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
676
744
716
542
2,678
2025
742
717
- -
597
2,797
2026
820
782
844
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.18
-0.18
-0.79
-0.68
2025
0.18
-0.08
- -
-0.52
-0.41
2026
0.47
0.12
0.42
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.03
0.43
0.04
0.52
2025
0.02
0.03
- -
-0.03
0.12
2026
0.03
0.03
0.33
- -
- -

Company Description

CEO
Liang Jin
Full Time Employees
5,018
Sector
Health services
Industry
Hospital/Nursing management
Address
Shanghai China
IPO Date
Jul 5, 2022
Business
Bright Eye Hospital Group Co., Ltd. is a China-based healthcare provider specializing in the provision of comprehensive ophthalmic medical services and optical products. Founded in 2005 and headquartered in Chengdu, Sichuan Province, China, the company operates a nationwide chain of specialized eye hospitals and outpatient clinics across major metropolitan markets, including Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, Wuhan, Kunming, Lanzhou, Hefei, Zhengzhou, and Xi'an. The company organizes its core clinical operations across several specialized departments and service lines: refractive surgery services, featuring laser-assisted and lens-based vision correction procedures such as small incision lenticule extraction (SMILE and SMILE Pro), femtosecond laser-assisted in situ keratomileusis (FS-LASIK), transepithelial photorefractive keratectomy (TransPRK), and implantable collamer lens (ICL and TICL) surgeries; cataract diagnostic and surgical treatments, encompassing ultrasonic phacoemulsification, femtosecond laser-assisted cataract surgery, and premium intraocular lens (IOL) implantations including multifocal, toric, and extended depth of focus lenses; optometry and pediatric ophthalmology services, providing comprehensive medical optometric evaluations, amblyopia and strabismus therapies, vision training, and the dispensing of corrective spectacles, soft contact lenses, and orthokeratology (OK) lenses for juvenile myopia management; fundus and vitreoretinal care, involving vitrectomy, retinal laser photocoagulation, and anti-VEGF intraocular injections for diabetic retinopathy, retinal detachment, and age-related macular degeneration; ocular surface and corneal disease treatments, including corneal transplantation, keratoplasty, pterygium excision, and specialized dry eye therapies; glaucoma management, offering diagnostic tracking, medical management, laser iridotomy, and trabeculectomy; and oculoplastic, orbital, and lacrimal duct surgeries. Beyond direct clinical care, the group engages in hospital management, clinical ophthalmic research, ophthalmic medical device and instrument trading, and optical retail operations. In recent corporate developments, the company changed its legal name from Chengdu Bright Eye Hospital Group Co., Ltd. to Bright Eye Hospital Group Co., Ltd. in June 2025 to reflect its nationwide footprint and corporate scale. The company has continued its strategic capacity expansion by establishing and opening new medical centers across key provincial capitals and tier-one cities—including new facilities in Guangzhou, Shenzhen, Shanghai, Kunming, and Fuzhou—along with allocating capital toward the development of the Chengdu Jinjiang Bright Eye Hospital and the establishment of Chengdu Xingyao Bright Eye Hospital. The group has also pursued strategic diversification into adjacent healthcare and supply chain segments through investments in medical aesthetics via Qingdao Luxi Medical Beauty and medical apparatus distribution through Nantong Youci Medical Devices. Operationally, the company entered a strategic partnership with ByteDance's Feishu platform to build an integrated digital smart healthcare platform to streamline hospital administration, clinical workflows, and patient management, while concurrently deploying next-generation surgical equipment including SMILE Pro laser systems across its surgical suites. In corporate governance, the company appointed Wen Gao as General Manager in July 2026 to lead operational optimization and ongoing clinical network development.